DLCO has been shown to be a predictor of survival time in ILD patients32 including RA–ILD35 and myositis–ILD.36 Although 4 deaths were recorded in the ACPA-negative group versus none in the ACPA-positive group, difference in survival between the 2 groups did not reach statistical significance despite prolonged follow-up. This evidence concerns the gene PRTN3 and rheumatoid arthritis.